As a clinician, not a statistician, it is sometimes a struggle to evaluate the conclusion of trials. It has always seemed to me that studies of treatments for coronary artery disease should be not only understandable for the practitioner but also for the patients. What do patients want to know about treatment options, whether they are for primary or secondary prevention, or for relief of symptoms? Despite a great amount of nuanced information being available to the public, the heart carries a certain amount of emotional attachment when the patient learns that there is something wrong with it. People who have, or have been told they may develop, heart disease begin to consider how long they will be around and all that comes with those thoughts. The concern about their mortality is a reasonable concern and one that patients expect some new treatments to positively affect.